Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov:148:104484.
doi: 10.1016/j.micpath.2020.104484. Epub 2020 Sep 9.

Immune response in COVID-19: What do we currently know?

Affiliations
Review

Immune response in COVID-19: What do we currently know?

Daniela S Oliveira et al. Microb Pathog. 2020 Nov.

Abstract

In 2002/2003 there was a pandemic denominate SARS (severe acute respiratory syndrome), caused by the SARS-CoV virus that belongs to the genera Betacoranavirus and the family Coronaviridae, generally responsible for influenza infections. In mid of 2019, a new disease by the coronavirus named by COVID-19 (SARS-CoV-2) emerged, both infections have flu symptoms, however they are infections that variable intensity, being medium to severe. In medium infections individuals have the virus and exhibit symptoms, however hospitalization is not necessary, in severe infections, individuals are hospitalized, have high pathology and in some cases progress to death. The virus is formed by simple positive RNA, enveloped, non-segmented, and presenting the largest genome of viruses constituting 32 Kb, consisting of envelope proteins, membrane, nucleocapsid and spike protein, which is essential in the interaction with the host cells. As for the origin of this virus, research has been intensified to determine this paradox and although the similarity with SARS-CoV, this virus did not has necessarily the same place of origin. As for the immune system, it is currently unknown how this new virus interacts. In this brief review, we demonstrate important considerations about the responses to this infection.

PubMed Disclaimer

Conflict of interest statement

All authors declare no commercial or financial conflict of interest.

Figures

Fig. 1
Fig. 1
Representative design of the essential structures of the coronavirus.
Fig. 2
Fig. 2
Representative design of the viral replication cycle (SARS-Cov).

Similar articles

Cited by

References

    1. WHO-World Health Organization Mers situation update. 2020. http://applications.emro.who.int/docs/Emrpub-Csr-241-2019-En.pdf?ua=1&ua... Available in:
    1. Chan K.H. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229e, Oc43, and Nl63. Clin. Diagn. Lab. Immunol. 2005;12(11):1317–1321. In .Gorse, G. J.; Donovan, M.M.; Patel, G. B. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus‐associated illnesses. Journal of Medical Virology, feb.2020. - PMC - PubMed
    1. Lim Y.X., Ng Y.L., Tam J.P., Liu D.X. Human coronaviruses: a review of virus–host interactions. Diseases. 2016;4(3):26. jul.2016.In Gorse, G. J.; Donovan, M.M.; Patel, G. B. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus‐associated illnesses. Journal of Medical Virology, feb.2020. - PMC - PubMed
    1. Zhao J. Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses. Sci. Immunol. aug.2017;2(14) In. Channappanavar, R.; Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. In: Seminars in immunopathology. Springer Berlin Heidelberg, pp. 529–539, feb. 2017. - PMC - PubMed
    1. Gorbalenya A.E. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. mar.2020;5:536–544. - PMC - PubMed

Substances